1. Llorente JL, López F, Suárez C, Hermsen MA. Sinonasal carcinoma:
clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol. agosto de 2014;11(8):460-72.
2. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. junio de 2012;34(6):877-85.
3. Luis Llorente J, Núñez F, Pablo Rodrigo J, Fernández León R, Álvarez C, Hermsen M, et al. Adenocarcinomas nasosinusales: nuestra experiencia.
Acta Otorrinolaringológica Esp. 1 de mayo de 2008;59(5):235-8.
4. Llorente JL, Pérez-Escuredo J, Alvarez-Marcos C, Suárez C, Hermsen M.
Genetic and clinical aspects of wood dust related intestinal-type sinonasal adenocarcinoma: a review. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. enero de 2009;266(1):1-7.
5. Pérez-Escuredo J, Martínez JG, Vivanco B, Marcos CÁ, Suárez C, Llorente JL, et al. Wood dust–related mutational profile of TP53 in intestinal-type sinonasal adenocarcinoma. Hum Pathol. 1 de noviembre de 2012;43(11):1894-901.
6. Barnes L. Schneiderian papillomas and nonsalivary glandular neoplasms of the head and neck. Mod Pathol Off J U S Can Acad Pathol Inc. marzo de 2002;15(3):279-97.
7. Duprez F, Madani I, Morbée L, Bonte K, Deron P, Domján V, et al. IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival. Int J Radiat Oncol Biol Phys. 1 de mayo de 2012;83(1):252-9.
8. Vivanco Allende B, Perez-Escuredo J, Fuentes Martínez N, Fresno Forcelledo MF, Llorente Pendás JL, Hermsen M. Adenocarcinomas
35 nasosinusales tipo intestinal. Perfil inmunohistoquímico de 66 casos. Acta Otorrinolaringológica Esp. 1 de marzo de 2013;64(2):115-23.
9. Muzzey D, Evans EA, Lieber C. Understanding the Basics of NGS: From Mechanism to Variant Calling. Curr Genet Med Rep. 2015;3(4):158-65.
10. Nicolai P, Schreiber A, Bolzoni Villaret A, Lombardi D, Morassi L, Raffetti E, et al. Intestinal type adenocarcinoma of the ethmoid: Outcomes of a treatment regimen based on endoscopic surgery with or without radiotherapy. Head Neck. abril de 2016;38 Suppl 1:E996-1003.
11. Holmila R, Cyr D, Luce D, Heikkilä P, Dictor M, Steiniche T, et al. COX-2 and p53 in human sinonasal cancer: COX-2 expression is associated with adenocarcinoma histology and wood-dust exposure. Int J Cancer. 1 de mayo de 2008;122(9):2154-9.
12. Hermsen MA, Riobello C, García-Marín R, Cabal VN, Suárez-Fernández L, López F, et al. Translational genomics of sinonasal cancers. Semin Cancer Biol. 1 de abril de 2020;61:101-9.
13. Udager AM, McHugh JB, Goudsmit CM, Weigelin HC, Lim MS, Elenitoba- Johnson KSJ, et al. Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas. Ann Oncol Off J Eur Soc Med Oncol. 1 de febrero de 2018;29(2):466-71.
14. Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev. enero de 2018;62:50-60.
15. Syrjänen K, Syrjänen S. Detection of human papillomavirus in sinonasal papillomas: systematic review and meta-analysis. The Laryngoscope.
enero de 2013;123(1):181-92.
36 16. Díaz-Molina JP, Llorente JL, Vivanco B, Martínez-Camblor P, Fresno MF, Pérez-Escuredo J, et al. Wnt-pathway activation in intestinal-type sinonasal adenocarcinoma. Rhinology. diciembre de 2011;49(5):593-9.
17. López F, García Inclán C, Pérez-Escuredo J, Alvarez Marcos C, Scola B, Suárez C, et al. KRAS and BRAF mutations in sinonasal cancer. Oral Oncol. agosto de 2012;48(8):692-7.
18. Licitra L, Resteghini C, Bossi P. The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer. Adv Otorhinolaryngol.
2020;84:78-86.
19. Youlden DR, Cramb SM, Peters S, Porceddu SV, Møller H, Fritschi L, et al. International comparisons of the incidence and mortality of sinonasal cancer. Cancer Epidemiol. 1 de diciembre de 2013;37(6):770-9.
20. Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 30 de mayo de 2013;497(7451):638- 42.
21. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer:
mechanisms and advances in clinical trials. Mol Cancer. 19 de febrero de 2019;18(1):26.
22. Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Swords RT, Roboz GJ, et al.
Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS). Blood. 2 de diciembre de 2016;128(22):343.
23. Kamel D, Gray C, Walia JS, Kumar V. PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. Curr Drug Targets. 2018;19(1):21-37.
37 24. Choussy O, Ferron C, Védrine PO, Toussaint B, Liétin B, Marandas P, et al. Adenocarcinoma of Ethmoid: A GETTEC Retrospective Multicenter Study of 418 Cases. The Laryngoscope. 2008;118(3):437-43.
25. Hoeben A, van de Winkel L, Hoebers F, Kross K, Driessen C, Slootweg P, et al. Intestinal-type sinonasal adenocarcinomas: The road to molecular diagnosis and personalized treatment. Head Neck. octubre de 2016;38(10):1564-70.
26. Ansa B, Goodman M, Ward K, Kono SA, Owonikoko TK, Higgins K, et al.
Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009.
Cancer. 15 de julio de 2013;119(14):2602-10.
27. Camp S, Van Gerven L, Poorten VV, Nuyts S, Hermans R, Hauben E, et al. Long-term follow-up of 123 patients with adenocarcinoma of the sinonasal tract treated with endoscopic resection and postoperative radiation therapy. Head Neck. febrero de 2016;38(2):294-300.
28. Choussy O, Ferron C, Védrine PO, Toussaint B, Liétin B, Marandas P, et al. Role of radiotherapy in the treatment of nasoethmoidal adenocarcinoma. Arch Otolaryngol Head Neck Surg. febrero de 2010;136(2):143-6.
29. Chen MM, Roman SA, Sosa JA, Judson BL. Predictors of Survival in Sinonasal Adenocarcinoma. J Neurol Surg Part B Skull Base. junio de 2015;76(3):208-13.
30. Suarez C, Llorente JL, Fernandez De Leon R, Maseda E, Lopez A.
Prognostic factors in sinonasal tumors involving the anterior skull base.
Head Neck. febrero de 2004;26(2):136-44.
31. Fiaux-Camous D, Chevret S, Oker N, Turri-Zanoni M, Lombardi D, Choussy O, et al. Prognostic value of the seventh AJCC/UICC TNM classification of intestinal-type ethmoid adenocarcinoma: Systematic review and risk prediction model. Head Neck. abril de 2017;39(4):668-78.
38 32. Sánchez-Fernández P, Riobello C, Costales M, Vivanco B, Cabal VN, García-Marín R, et al. Next-generation sequencing for identification of actionable gene mutations in intestinal-type sinonasal adenocarcinoma.
Sci Rep. 26 de enero de 2021;11(1):2247.
33. L B, JW E, P R, D S. Pathology and Genetics of Head and Neck Tumours [Internet]. [citado 4 de mayo de 2023]. Disponible en:
https://publications.iarc.fr/Book-And-Report-Series/Who-Classification- Of-Tumours/Pathology-And-Genetics-Of-Head-And-Neck-Tumours-2005
39 ANEXOS